The KRAS protein, a key cancer driver, was long considered an "undruggable target" due to its smooth, pocketless structure, likened to a golf ball. The breakthrough was a "molecular glue" that attaches another protein to KRAS, altering its shape and deactivating its malignant function, bypassing the need to fit into a non-existent pocket.
A major drug approval risks slowing future progress if it leads to widespread off-label use instead of continued clinical trial enrollment. This approach bypasses the systematic data collection needed to understand optimal use, combinations, and next-generation therapies, potentially stalling the very progress the breakthrough represents.
Counterintuitively, the pivotal Resolute 302 trial for the KRAS-targeting drug Daraxonrasib was not limited to patients with KRAS mutations. It also enrolled patients with any mutation or even no mutation at all. While this broadens the scope, the study was not powered to determine the drug's efficacy in the small non-KRAS subgroup.
The higher quality of life reported by patients on Daraxonrasib compared to chemotherapy may be influenced by psychological factors. Since patients knew which treatment they were receiving, the positive perception of being on a novel "breakthrough drug" versus standard chemo could have biased their self-reported outcomes, a crucial nuance in data interpretation.